Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Expression of CD38 and High Levels of CD5 Identifies Members of CLL Clones That Have Progressed beyond G1 and Proliferated.

Carlo Calissano, MD, Rajendra N. Damle, PhD, Marc Hellerstein, MD, Elisabeth J. Murphy, MD, Gregory M. Hayes, PhD, Kaufman Matthew, MD, Steven Allen, MD, Kanti Rai, MD, Nicholas Chiorazzi, MD

Blood (2007) 110 (11): 1114.

https://doi.org/10.1182/blood.V110.11.1114.1114

Published: 2007

Journal Articles

In Vivo Labeling of Newly Synthesized DNA Suggests That the CD38 + Fraction Is Enriched in Proliferating Cells within a Clone of Chronic Lymphocytic Leukemia B Cells.

Carlo Calissano, MD, Rajendra Damle, PhD, Taraneh Banapour, BS, Denise Cesar, Marc Hellerstein, MD, PhD, Steven Allen, MD, Kanti Rai, MD, Nicholas Chiorazzi, MD

Blood (2006) 108 (11): 27.

https://doi.org/10.1182/blood.V108.11.27.27

Published: 2006

Journal Articles

Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.

Richard L. Piekarz, MD PhD, Robin Frye, RN, Maria Turner, MD, John Wright, MD, PhD, Steven Allen, MD, Mark H. Kirschbaum, MD, Jasmine Zain, MD, Miles Prince, MD, Laura Hutchins, MD, Louise C. Showe, PhD, William D. Figg, PharmD, Tito Fojo, MD, PhD, Susan E. Bates, MD, for All Collaborators

Blood (2006) 108 (11): 2469.

https://doi.org/10.1182/blood.V108.11.2469.2469

Published: 2006

Journal Articles

Genome Analysis of CLL by Representational Oligonucleotide Microarray Analysis (ROMA).

Vladimir D. Grubor, PhD, Jennifer E. Troge, B.S, Jennifer L. Meth, B.S., B. Lakshmi, Ph.D., Boris Yamron, Ph.D., Lisa A. Hufnagel, M.S., Yoon-Ha Lee, Ph.D., Jude T. Kendall, B.S., Deepa Pai, M.S., Annette Lee, Ph.D., Peter Gregersen, M.D., Sophia Yancopoulos, Ph.D., Steven Allen, M.D., Kanti R. Rai, M.D., Nicholas Chiorazzi, M.D., Michael H. Wigler, Ph.D., Diane Esposito, Ph.D.

Blood (2006) 108 (11): 2085.

https://doi.org/10.1182/blood.V108.11.2085.2085

Published: 2006

Journal Articles

Results of a Multi-Center, Phase II Study of Elsamitrucin (SPI-28090) in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL).

Kenneth Foon, MD, Steven Allen, MD, Kaushik Sen, MD, Ann Mohrbacher, MD, Shamel Sanani, MD, Luigi Lenaz, MD, Rosamerlinda Rosales, MD

Blood (2005) 106 (11): 4741.

https://doi.org/10.1182/blood.V106.11.4741.4741

Published: 2005

Journal Articles

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Richard L. Piekarz, MD, PhD, Robin Frye, RN, Maria Turner, MD, John Wright, MD, PhD, Steven Allen, MD, Mark H. Kirschbaum, MD, Jasmine Zain, MD, Miles Prince, MD, Susan E. Bates, MD, for All Collaborators

Blood (2005) 106 (11): 231.

https://doi.org/10.1182/blood.V106.11.231.231

Published: 2005

NARROW

Expression of CD38 and High Levels of CD5 Identifies Members of CLL Clones That Have Progressed beyond G1 and Proliferated.

In Vivo Labeling of Newly Synthesized DNA Suggests That the CD38 + Fraction Is Enriched in Proliferating Cells within a Clone of Chronic Lymphocytic Leukemia B Cells.

Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.

Genome Analysis of CLL by Representational Oligonucleotide Microarray Analysis (ROMA).

Results of a Multi-Center, Phase II Study of Elsamitrucin (SPI-28090) in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL).

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Email alerts

ASH Publications

American Society of Hematology

Expression of CD38 and High Levels of CD5 Identifies Members of CLL Clones That Have Progressed beyond G1 and Proliferated.

In Vivo Labeling of Newly Synthesized DNA Suggests That the CD38 + Fraction Is Enriched in Proliferating Cells within a Clone of Chronic Lymphocytic Leukemia B Cells.

Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers.

Genome Analysis of CLL by Representational Oligonucleotide Microarray Analysis (ROMA).

Results of a Multi-Center, Phase II Study of Elsamitrucin (SPI-28090) in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL).

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only